RECORD 1

TITLE

Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials

AUTHOR NAMES

Tombal B.F.; Armstrong A.J.; Barrus J.K.; Beer T.M.; Chowdhury S.; Evans C.P.; Heidenreich A.; Higano C.S.; Kamba T.; Lin P.; Nikolayeva N.; Sugg J.; Steinberg J.L.; Taplin M.E.; Saad F.

AUTHOR ADDRESSES

(Tombal B.F.; Armstrong A.J.; Barrus J.K.; Beer T.M.; Chowdhury S.; Evans C.P.; Heidenreich A.; Higano C.S.; Kamba T.; Lin P.; Nikolayeva N.; Sugg J.; Steinberg J.L.; Taplin M.E.; Saad F.) Cliniques Universitaires Saint-Luc, Brussels, Belgium; Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, NC; Astellas Pharma, Inc., Northbrook, IL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Guy's, King's and St. Thomas' Hospitals, London, United Kingdom; University of California, Davis, School of Medicine, Sacramento, CA; Department of Urology and Uro-Oncology, University Hospital of Cologne, Cologne, Germany

CORRESPONDENCE ADDRESS

B.F. Tombal,

FULL RECORD ENTRY DATE

2019-04-16

SOURCE

Journal of Clinical Oncology (2019) 37 Supplement 7. Date of Publication: 1 Mar 2019

VOLUME

37

DATE OF PUBLICATION

1 Mar 2019

CONFERENCE NAME

2019 Gastrointestinal Cancers Symposium

CONFERENCE LOCATION

San Francisco, CA, United States

CONFERENCE DATE

2019-02-14 to 2019-02-16

ISSN

1527-7755

BOOK PUBLISHER

American Society of Clinical Oncology

ABSTRACT

Background: Androgen receptor inhibitor enzalutamide improves survival in patients with metastatic CRPC (mCRPC) and reduces risk of metastasis or death versus placebo in patients with non-metastatic CRPC (nmCRPC). This post hoc analysis evaluated the incidence of adverse events (AEs) of special interest reported with enzalutamide versus placebo in CRPC trials. Methods: Safety data from four Phase 3, placebo-controlled enzalutamide trials in men with CRPC (PROSPER, nmCRPC, NCT02003924; PREVAIL, mCRPC, NCT01212991; AFFIRM, mCRPC, NCT00974311; and 9785-CL-0232, mCRPC, NCT02294461) were assessed for AEs of special interest, including ischemic heart disease (IHD) [defined by narrow Standardised MedDRA Queries “Myocardial Infarction”/“Other Ischemic Heart Disease”], falls, and fractures. Data were reported as overall incidence and adjusted for treatment exposure (per 100 patient-years), and summarized as follows: patients receiving enzalutamide (n = 2799) and placebo (n = 1898) in all four Phase 3 trials. Results: Median treatment duration was 13.73 months with enzalutamide and 4.80 months with placebo in the combined Phase 3 trials. Overall incidence of IHD was higher with enzalutamide versus placebo in the combined Phase 3 trials (Table), remaining higher once adjusted for treatment exposure (2.5 with enzalutamide vs. 2.2 with placebo). Similarly, exposure-adjusted rate of falls and fractures were also higher with enzalutamide versus placebo (Table).Conclusions: In this combined analysis of CRPC trials, incidences of IHD, falls, and fractures were higher with enzalutamide versus placebo in all patients. Efforts to identify patients at high risk for these AEs and reduce their risk, e.g. via exercise and cardiovascular risk reduction, are important in these patients, particularly in elderly men and those with cardiovascular comorbidities. (Table Presented).

EMTREE DRUG INDEX TERMS (MAJOR FOCUS)

enzalutamide

EMTREE DRUG INDEX TERMS

placebo

EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)

castration resistant prostate cancer; drug safety

EMTREE MEDICAL INDEX TERMS

adverse drug reaction; aged; cancer patient; cardiovascular risk; comorbidity; conference abstract; controlled study; death; drug therapy; exercise; fracture; heart infarction; human; incidence; major clinical study; male; Medical Dictionary for Regulatory Activities; metastasis; pharmacokinetics; phase 3 clinical trial; side effect; treatment duration

CAS REGISTRY NUMBERS

enzalutamide (915087-33-1)

LANGUAGE OF ARTICLE

English

LANGUAGE OF SUMMARY

English

PUI

L627164027

COPYRIGHT